Ardelyx drug reduces elevated phosphate levels, late-stage study shows

Ardelyx Inc's experimental drug has shown promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease (CKD), the drugmaker said on Tuesday.